Former EMA head to advise NDA Group business

Thomas Lönngren joins new European regulatory and market access business

Independent consultancy the NDA Group has launched NDA Advisory Services, a regulatory and market access business to be based in London, UK that aims to cut the rising cost of new medicines and address the challenges of drug regulation and reimbursement, to ensure that new medicines can get to patients faster.

Thomas Lönngren, previously executive director of the European Medicines Agency (EMA), will take a strategic advisory role in the new business.

The organisation said NDA’s Advisory Board would be integral integral to NDA Advisory Services and will be expanded to include HTA and market access capabilities.

New specialists are to join the Advisory Board to advise pharmaceutical companies on how they can prove the value of their products to national agencies.

Lönngren will play a fundamental role in the new business, building on 30 years’ experience in the regulatory field including the last 10 years heading EMA. One of his key ambitions is to create a co-ordinated approach to Health Technology Assessment and improve market access in Europe.

‘I’ve recognised for a long time that the whole area of market access needs new ideas and a new vision,’ he said.

‘I plan to further develop my ideas surrounding International Regulatory Strategies, coupled with pushing for a joined-up approach to HTA, to enable the best medicines to reach needy patients as efficiently as possible.’

NDA has offices in Germany, Sweden and the UK.

You may also like

Regulatory

Amcor’s Winterbourne site achieves ISO 13485 certification, strengthening its position and capabilities in healthcare

ISO 13485:2016 is an internationally recognised quality management standard specifically for medical devices.
Regulatory

Roche wins CE mark for first blood-based immunoassay to identify ApoE4 Alzheimer's risk variant

Roche's Elecsys ApoE4 test has received CE mark approval as the first in-vitro diagnostic immunoassay to detect the ApoE4 genetic variant from a simple blood sample, potentially eliminating the need for confirmatory DNA testing in Alzheimer's patients who do not carry the variant
Regulatory

Orphan drug sales to exceed $400bn by 2032, Evaluate report finds

Despite FDA policy shifts and the rise of blockbuster obesity drugs, a new Evaluate report confirms rare disease therapies are on track to claim more than a fifth of all global prescription drug sales within a decade
Regulatory

Shilpa Biologicals and mAbTree secure FDA Orphan Drug Designation for rare blood cancer biologic

The FDA has granted Orphan Drug Designation to the pair's investigational monoclonal antibody for Essential Thrombocythemia and Polycythemia Vera, two rare chronic blood cancers with significant unmet treatment need
Media

CBA releases statement welcoming government's decision to incude biocides in post-Brexit negotiations

Biocides have now been officially included in the scope of negotiations, which the association has called an "important and practical step towards cutting red tape and restoring clarity for businesses," though the "reality is that much more still needs to be done"
Manufacturing

Lonza and Genetix extend commercial manufacturing agreement for ZYNTEGLO™

Expanded collaboration will support growing demand for FDA-approved gene therapy for beta-thalassemia
Regulatory

Orbia Fluor & Energy Materials registers US DMF file for low-GWP propellant

The fluor-based product manufacturer announced the creation of a US Type IV Drug Master File (DMF) for the low-GWP excipient Zephex 152a, with pharma companies now able to reference the data package for faster, lower-risk FDA reviews for pMDIs
Subscribe now